The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Resistance of Crohn’s Disease T Cells to Multiple Apoptotic Signals Is Associated with a Bcl-2/Bax Mucosal Imbalance
Open accessAbstract
Crohn’s disease (CD) is a condition characterized by excessive numbers of activated T cells in the mucosa. We investigated whether a defect in apoptosis could prolong T cell survival and contribute to their accumulation in the mucosa. Apoptotic, Bcl-2+, and Bax+ cells in tissue sections were detected by the TUNEL method and immunohistochemistry. T cell apoptosis was induced by IL-2 deprivation, Fas Ag ligation, and exposure to TNF-α and nitric oxide. TUNEL+ leukocytes were few in control, CD, and ulcerative colitis (UC) mucosa, with occasional CD68+ and myeloperoxidase+, but no CD45RO+, apoptotic cells. Compared with control and UC, CD T cells grew remarkably more in response to IL-2 and were significantly more resistant to IL-2 deprivation-induced apoptosis. CD T cells were also more resistant to Fas- and nitric oxide-mediated apoptosis, whereas TNF-α failed to induce cell death in all groups. Compared with control, CD mucosa contained similar numbers of Bcl-2+, but fewer Bax+, cells, while UC mucosa contained fewer Bcl-2+, but more Bax+, cells. Hence, the Bcl-2/Bax ratio was significantly higher in CD and lower in UC. These results indicate that CD may represent a disorder where the rate of T cell proliferation exceeds that of cell death. Insufficient T cell apoptosis may interfere with clonal deletion and maintenance of tolerance, and result in inappropriate T cell accumulation contributing to chronic inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Social controls on cell survival and cell death
Raff, M. C. (1992) · Nature · doi:10.1038/356397a0 · Cited by 2,604
Mechanisms and Genes of Cellular Suicide
Steller, H. (1995) · Science · doi:10.1126/science.7878463 · Cited by 2,479
Oxidative stress as a mediator of apoptosis
Buttke, T. M., & Sandstrom, P. A. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90018-3 · Cited by 2,165
Inflammatory bowel disease: Etiology and pathogenesis
Fiocchi, C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70381-6 · Cited by 2,059
Self-citationThe proto-oncogene Bcl-2 and its role in regulating apoptosis
Kroemer, G. (1997) · Nature Medicine · doi:10.1038/nm0697-614 · Cited by 1,739
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
Cited by
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Inflammatory bowel disease: cause and immunobiology
Baumgart, D. C., & Carding, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60750-8 · Cited by 2,147
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111
Immunopathogenesis of IBD: current state of the art
de Souza, H. S. P., & Fiocchi, C. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.186 · Cited by 1,551
Self-citationAtreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., & Rose‐John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 641
Inducible Nitric Oxide Synthase and Inflammatory Diseases
Zamora, R., Vodovotz, Y., & Billiar, T. R. (2000) · Molecular Medicine · doi:10.1007/bf03401781 · Cited by 558
Ciccocioppo, R., Bernardo, M. E., Sgarella, A., Maccario, R., Avanzini, M. A., Ubezio, C., Minelli, A., Alvisi, C., Vanoli, A., Calliada, F., et al. (2011) · Gut · doi:10.1136/gut.2010.214841 · Cited by 558
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
ten Hove, T. (2002) · Gut · doi:10.1136/gut.50.2.206 · Cited by 545
Angiogenesis and chronic inflammation: cause or consequence?
Costa, C., Incio, J., & Soares, R. (2007) · Angiogenesis · doi:10.1007/s10456-007-9074-0 · Cited by 504
Shanahan, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07284-7 · Cited by 478
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Oxidative stress as a pathogenic factor in inflammatory bowel disease — radicals or ridiculous?
Kruidenier, L., & Verspaget, H. W. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01378.x · Cited by 392
Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics
Shanahan, F. (2001) · Gastroenterology · doi:10.1053/gast.2001.22122 · Cited by 371
Etiopathogenesis of inflammatory bowel diseases
Danese, S., & Fiocchi, C. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.12.4807 · Cited by 327
Self-citationBorruel, N., Carol, M., Casellas, F., Antolín, M., de Lara, F., Espín, E., Naval, J., Guarner, F., & Malagelada, J. R. (2002) · Gut · doi:10.1136/gut.51.5.659 · Cited by 326
Involvement of IL–6 in the pathogenesis of inflammatory bowel disease and colon cancer
Atreya, R., & Neurath, M. F. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:3:187 · Cited by 324
Inflammation-Induced Endothelial-to-Mesenchymal Transition
Rieder, F., Kessler, S. P., West, G. A., Bhilocha, S., de la Motte, C., Sadler, T. M., Gopalan, B., Stylianou, E., & Fiocchi, C. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.042 · Cited by 322
Self-citationLoci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease
Kugathasan, S., Baldassano, R. N., Bradfield, J. P., Sleiman, P. M. A., Imielinski, M., Guthery, S. L., Cucchiara, S., Kim, C. E., Frackelton, E. C., Annaiah, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.203 · Cited by 316
Do tumor necrosis factor inhibitors cause uveitis? A registry‐based study
Lim, L. L., Fraunfelder, F. W., & Rosenbaum, J. T. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22918 · Cited by 315
TNFα blockade in human diseases: Mechanisms and future directions
Wong, M., Ziring, D., Korin, Y., Desai, S., Kim, S., Lin, J., Gjertson, D., Braun, J., Reed, E., & Singh, R. R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.08.013 · Cited by 307
Zeissig, S., Bojarski, C., Buergel, N., Mankertz, J., Zeitz, M., Fromm, M., & Schulzke, J. D. (2004) · Gut · doi:10.1136/gut.2003.036632 · Cited by 305
The host–microbe interface within the gut
Shanahan, F. (2002) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2002.0342 · Cited by 299
Biologic Therapy for Inflammatory Bowel Disease
Ardizzone, S., & Bianchi Porro, G. (2005) · Drugs · doi:10.2165/00003495-200565160-00002 · Cited by 280
IBD immunopathogenesis: A comprehensive review of inflammatory molecules
Park, J. H., Peyrin-Biroulet, L., Eisenhut, M., & Shin, J. I. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.02.013 · Cited by 276
Galectin-1 suppresses experimental colitis in mice
Santucci, L., Fiorucci, S., Rubinstein, N., Mencarelli, A., Palazzetti, B., Federici, B., Rabinovich, G. A., & Morelli, A. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00267-1 · Cited by 256
Immune dysfunction in inflammatory bowel disease
Neuman, M. G. (2007) · Translational Research · doi:10.1016/j.trsl.2006.11.009 · Cited by 255
Recent understanding of IBD pathogenesis: Implications for future therapies
Kucharzik, T., Maaser, C., Lügering, A., Kagnoff, M., Mayer, L., Targan, S., & Domschke, W. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000235827.21778.d5 · Cited by 254
Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors
Cramer, P., & Bresalier, R. S. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0540-6 · Cited by 167
Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets
Xiong, Q., Ancona, N., Hauser, E. R., Mukherjee, S., & Furey, T. S. (2012) · Genome Research · doi:10.1101/gr.124370.111 · Cited by 103
Sun, W., Han, X., Wu, S., Wu, J., Yang, C., & Li, X. (2020) · Inflammopharmacology · doi:10.1007/s10787-019-00678-2 · Cited by 31
Metadata
- Authors
- Ina, K., Itoh, J., Fukushima, K., Kusugami, K., Yamaguchi, T., Kyokane, K., Imada, A., Binion, D. G., Musso, A., West, G. A., Dobrea, G. M., McCormick, T. S., Lapetina, E. G., Levine, A. D., Ottaway, C. A., & Fiocchi, C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-07
- Volume
- 163
- Issue
- 2
- Pages
- 1081-1090
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1553717629
- Cited by
- 345
- References
- 57
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.